Cao Lili, Liu Yingying, Lin Guimei
Student Counseling Center, Shandong University, Jinan 250012, China.
School of Pharmaceutical Science, Shandong University, Jinan 250012, China.
Int J Mol Sci. 2025 Mar 30;26(7):3206. doi: 10.3390/ijms26073206.
Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective strategy for the treatment of hematological malignancies. At present, how to prepare CAR-T cells efficiently, quickly, and safely is one of the urgent problems to be solved. The durability and activity of engineered T cells in solid tumors need to be further improved, and the strategy of T cells penetrating the tumor microenvironment also needs to be improved. In addition, although the problems mainly caused by T-cell biology are being solved, the manufacturing mode and process still need to be improved to ensure that CAR-T cell therapy can be widely used. This paper summarizes some strategies that can improve the efficacy of CAR-T cells.
嵌合抗原受体（CAR）T细胞疗法已被证明是治疗血液系统恶性肿瘤的有效策略。目前，如何高效、快速且安全地制备CAR-T细胞是亟待解决的问题之一。实体瘤中工程化T细胞的持久性和活性需要进一步提高，T细胞穿透肿瘤微环境的策略也有待改进。此外，尽管主要由T细胞生物学引起的问题正在得到解决，但制造模式和工艺仍需改进，以确保CAR-T细胞疗法能够广泛应用。本文总结了一些可提高CAR-T细胞疗效的策略。
